In October 2024, Laboratoires Pierre Fabre entered into a research agreement with biotech company XtalPi to identify novel bioactive candidates and molecular targets for clinical dermatology. The agreement sees the French pharmaceutical and dermo-cosmetics group integrate XtalPi’s artificial intelligence and quantum physics platform into its research operations.
The alliance signals how prestige dermo-cosmetics groups are adopting pharmaceutical discovery techniques to compress active ingredient R&D. By applying computational physics and high-throughput laboratory automation to skin biology, Pierre Fabre intends to replace traditional trial-and-error screening with predictive molecular design.
Quantum Physics and Robotic Synthesis
XtalPi’s platform operates by uniting computational physics, machine learning, and laboratory automation. At the computational layer, the system relies on quantum mechanical calculations to model atomic-level interactions between potential bioactive compounds and specific biological targets. Generative artificial intelligence algorithms then process these atomic models to design novel molecular candidates tailored to specific binding sites.
Once designed in silico, these candidates pass to automated robotic systems that physically synthesise and evaluate the compounds in rapid succession. Pierre Fabre stated that the collaboration intends to harness these computational tools to accelerate the discovery of targeted solutions for unmet dermatological conditions. XtalPi confirmed that combining its computational platform and automated lab capabilities with Pierre Fabre’s clinical dermatology expertise is structured to streamline the pipeline from candidate identification through to initial formulation research.
Shortening R&D Cycles
The move places Pierre Fabre within a wider trend as global cosmetic majors seek to compress their R&D cycles. Industry peers, including L'Oréal and Beiersdorf, have previously established tech-biotech research partnerships to reduce ingredient screening timelines from years to months, using predictive computational tools to filter out non-viable molecules before physical bench testing begins.
For Pierre Fabre, which manages a dual portfolio spanning prescription pharmaceuticals and dermo-cosmetic brands such as Eau Thermale Avène, the agreement draws upon its established medical orientation. Specific financial terms, executive leadership assignments, target dermatological conditions, and development timelines were not disclosed by either party.
The partnership's true test will come when its first AI-designed bioactive moves out of robotic screening and into clinical evaluation to prove chemical stability and bioavailability within complex topical formulations.